Combination therapy for inoperable liver cancer
Part of Cancer clinical trials.
This study tests a combination of two drugs (anlotinib and benmelstobart) with a liver-directed chemotherapy procedure (HAIC) in people with liver cancer that cannot be removed surgically. The goal is to see if this combo shrinks tumors and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 75 years old.
- Have been diagnosed with hepatocellular carcinoma that cannot be removed with surgery.
- Have not previously received systemic treatment for liver cancer, except possibly for a recurrence after surgery.
- Have at least one measurable tumor.
- Have adequate liver function (Child-Pugh score of 7 or less).
- Have adequate blood counts and organ function.
- Have controlled hepatitis B if you have it.
- Meet other standard safety criteria (e.g., no active bleeding, no recent heart attack, no other cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new combination therapy for liver cancer that cannot be surgically removed. It uses an immune-boosting drug (atezolizumab), a drug that blocks blood flow to tumors (bevacizumab), and a type of chemotherapy that is delivered directly into the liver artery (HAIC). This combination may help shrink liver tumors and improve outcomes.
This trial tests a combination of two drugs (benmelstobart and anlotinib) plus a precise form of radiation (SBRT) for people with liver cancer that has spread a little and has already stopped responding to first-line treatment. The goal is to see if this combination can help control the cancer better.
This study tests a combination of three treatments (HAIC, lenvatinib, and cadonilimab) as a way to shrink liver tumors that cannot be removed with surgery. The goal is to make the tumors smaller so they might be removed later, and to see how safe and effective this combination is.
This study tests a combination treatment for liver cancer that has not spread to other organs. It combines two procedures that deliver chemo directly to the liver (HAIC and TACE) with two medications (apatinib and camrelizumab) that help your immune system fight the cancer.
This trial tests a combined treatment plan—chemo delivered to the liver, targeted therapy, anti-VEGF therapy, and immunotherapy—to control unresectable hepatocellular carcinoma (HCC). It may help shrink tumors or slow progression when surgery isn’t possible.
This study tests a combination of liver-directed chemotherapy (given through a small tube into the liver artery), targeted therapy, and an immunotherapy drug (a PD-1 inhibitor) to help prevent liver cancer from coming back after surgery. It is for people whose tumor showed microvascular invasion, which raises the risk of recurrence.
Hear when a new Unresectable Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.